David M. Gamm, MD, PhD

David M. Gamm, MD, PhD

Professor, Emmett A. Humble Distinguished Director of the McPherson Eye Research Institute

Contact Administrative Support VISIT THE GAMM LAB

  • Diseases of the retina, stem cell biology
  • Human pluripotent stem cells
  • Disease modeling
  • Regenerative medicine
  • Retinitis pigmentosa
  • Age related macular degeneration
  • Retinal, photoreceptor, and RPE cell development
  • Retinal stem cell biology/human pluripotent stem cell biology
  • Retinal developmental biology
  • Inherited and acquired retinal degenerations
  • Cell and gene therapies for retinal degenerations
  • Stem cell-based retinal disease modeling

Affiliate Appointment:
Sandra Lemke Trout Chair in Eye Research

Pediatric and adult strabismus management and surgery, pediatric ophthalmology, genetic disorders, tear duct surgery, double vision, eyelid abnormalities

Pediatric Ophthalmology, University of Wisconsin Hospital and Clinics, Madison, WI

University of Wisconsin Hospital and Clinics, Madison, WI

Spectrum Hospital, Grand Rapids, MI

Medical School:
University of Michigan Medical School, Ann Arbor, MI

Additional Studies:
University of Michigan School of Graduate Studies, Ann Arbor, MI


Inherited and acquired eye diseases that culminate in the degeneration of photoreceptors and retinal pigment epithelium (RPE) are a significant cause of visual morbidity. The expansion and targeted differentiation of human stem and progenitor cells in vitro provide an essential source of biological material for modeling retinal development and potential cell-based treatments for these debilitating diseases. The aims of our laboratory are to 1) investigate cellular and molecular events that occur during retinogenesis and 2) provide cells for use in rescue or replacement therapies for retinal degenerative diseases.

To meet these goals, we utilize a variety of cell types. Retinal and neural progenitors are amenable to viral transformation and demonstrate the capacity to efficiently deliver neuroprotective factors directly to the retina. Human embryonic stem cells (hESCs) are used to delineate the genetic checkpoints necessary to produce a particular retinal cell type and serve as a model system for studying human retinal development. Lastly, we have developed a protocol to direct induced pluripotent stem cells (iPS) towards a retinal lineage in a manner similar to hESCs, which has allowed us to create cell-based models of human retinal degenerative diseases and begin transplantation experiments. By understanding the behavior of these cell types in vitro and in vivo, we hope to optimize strategies to delay or reverse the effects of inherited and acquired eye diseases such as retinitis pigmentosa and macular degeneration.